Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
GENFIT TOP M&A CANDIDATE he AtonRâ Global Healthcare M&A certificate fell 1.3% in November, underperforming the MSCI World Health Care Index by 3.4%. Launch-to-date (September 15, 2017), it underperforms its reference index by 3.2%. November was uneventful in terms of M&A newsflow in Biotech, MedTech and Pharma. This is to change in the coming months as it is our strong belief that all the catalysts are in place and the best days are ahead of us. We are just missing the needed trigger, which might come from the US tax reform. As chances of a successful US tax reform have substantially increased in recent weeks, we believe that Pharma industry’s CEOs are just waiting to see what the final version of the bill looks like before getting their artillery out. If the tax reform bill is sent to Mr. Trump’s desk for signature before Christmas, and with some very high-profile conferences taking place in the next weeks (ASH in December and JP Morgan in January 2018 notably), the needed trigger would be in place for a completely different M&A environment heading into 2018. We also believe that one deal (notably a high-profile one) would ignite fire to the overall sector and that a re-rating process would immediately take place. This is the main reason why currently we are completely invested in the space. On a therapeutic-specific note, we had the chance to meet with the head of Research of Genfit (part of our portfolio), a French company focused on NASH (non-alcoholic steatohepatitis), which is a leading cause of liver disease in developed countries and a $35B+ market untapped opportunity. The company (top M&A candidate in our view) is still open to deals/collaborations but as they just recently successfully raised capital (through EUR180m convertibles offering), we feel the company would only accept offers if the premium is high enough. They see themselves as a perfect fit for Gilead Sciences, which is currently in Phase 2-b on NASH with GS4997. Genfit believes (as everyone else in the Street) that their closest competitor, Intercept Pharmaceuticals, has too many problems to solve with Ocaliva and that Genfit might be the first and only viable option. While we might agree with this statement, we also believe that the NASH epidemic (between 5% and 12% of US and European populations) cannot be solved by a one-pill/one-treatment alone but rather a combo therapy. While Intercept’s problems (toxicity, pruritus in 23% of patients as well as an increase in LDL levels) look insurmountable to many and Allergan’s (through the huge bet they made in 2016 with the acquisition of Tobira) latest Phase 2 results showed no significant difference in Fibrosis improvement between Cenicriviroc and Placebo at year two (positive effects of CVC on fibrosis seen at one year disappear at two years), we believe all the above-mentioned companies are hot M&A plays.
Genfit a possible winner in NASH. And here they only talk about the USA.www.nashbiotechs.com/nash-biotech-ana...
Genfit gaat een hele mooie toekomst tegemoet. Interessant aandeel voor de lange termijn belegger.
Intercept Vs. Genfit: Who Is Winning The NASH Race? SummaryGenfit and Intercept are leading the NASH race.Scientifically not much to choose between the two.We give a slight edge to Intercept because of Genfit’s decision to commercialize elafibroanor all “Since you're indicating in this recent articlethat you will write another piece of analysis shortly, we would like to draw your attention to a crucial element that you seem to have missed about our future commercialization strategy. Indeed, as mentioned consistently over ime and here (no link) again recently, GENFIT's intention with elafibranor is to generate a double source of income, retaining rights of elafibranor in some territories, but also reserving a significant share of the market for future partnerships. Would therefore be great if you could update your last article, considering that the current version provides quite misleading information to your readers. If you're interested, we can also propose a quick catch-up call before you write your next article, to make sure you have an updated picture on other key elements of our comprehensive program in liver and metabolic diseases which aims at addressing challenges in NASH and PBC treatment, NASH diagnosis, and NASH disease awareness.“ After Gilead’s (GILD) Hepatitis-C franchise met with phenomenal success and equally phenomenal decline, focus shifted to a new area in the liver space - non-alcoholic steatohepatitis or NASH as it is more commonly known now. NASH is the next stage of non-alcoholic fatty liver disease or NAFLD and is characterized by liver damage and inflammation. NASH, if left untreated, eventually leads to advanced fibrosis, cirrhosis of the liver and ultimately hepatocellular carcinoma or HCC. The diagram below gives the different stages of the disease. Interest in the NASH space increased after a 2014 report from Deutsche Bank noting that the treatment market could be eventually worth more than $30 billion. That is from 0 to more than $30 billion in probably a decade. NASH was previously ignored by big biopharma as well as biotech companies. The reason was that up until a few years ago, NAFLD was seen as an effect of diabetes and therefore no treatment was developed for this disease. While it is true that obesity and type 2 diabetes do have a role to play in the advancement of the disease, recent researchhas shown that the disease can also occur in a significant proportion of NAFLD patients without diabetes. Recent research combined with the success of Gilead’s Hep C franchise and the Deutsche Bank report has therefore sparked significant interest in the NASH space. Not surprisingly, Gilead was initially seen as being a key player in the NASH space. However, what we have witnessed is intense competition and Gilead in fact is not even in the forefront. It must be noted here that Gilead has adopted a different strategy in the NASH space and is prepared to give up the chance to get to the market first. But this article is not focused on GILD’s NASH pipeline. It is focusing on the two companies that are unanimously seen as being at the forefront of the NASH treatment development. These companies are Intercept (ICPT) and French biotech Genfit (OTCPK:GNFTF). It has been a neck-and-neck race between the two companies, however, we believe that Intercept has the edge in the NASH treatment market as of now. And the edge is not based on the science. Intercept’s OCA vs. Genfit’s elafibranor Intercept is evaluating its obeticholic acid (OCA) in NASH. An agonist of farnesoid X receptor (‘FXR), OCA is already approved in the U.S. for the treatment of primary biliary cholangitis (‘PBC). OCA is marketed as Ocaliva in PBC. Since approval, Ocaliva has seen strong uptake despite some safety concerns. Genfit’s elafibranor on the other hand is an agonist of the peroxisome proliferator-activated receptors alpha and delta. Elafibranor has shown to improve insulin sensitivity, glucose homeostasis, and lipid metabolism. Both elafibranor and OCA are currently in Phase III development. And with the changes in the definition of NASH resolution (ballooning = 0; inflammation = 0-1; and steatosis = 0-3), we can now have an apple to apple comparison between the two during the Phase III trials, Genfit’s RESOLVE-IT and Intercept’s REGENERATE. The path to development has not been easy for two the companies. Given the vast number of NASH trials now in progress, enrollment has become a major issue. Both Intercept and Genfit (and in fact all Phase II and Phase III trials) have faced delays. The delay has pushed data readout to 2019 for both companies. Intercept in fact has gone and even reduced the number of patients it is enrolling for its Phase III trial. The patient reduction has allowed Intercept to cover some lost ground (a smart move in our opinion). Another smart thing ICPT has done is made changes to its endpoints. The earlier primary endpoint was fibrosis improvement and NASH resolution under new modified definition. The “and” has now been replaced with an “or,” which we believe lowers the bar somewhat. So after all the chopping and changing, here is how the two trials look like. Elafibranor Who has the edge? Scientifically there isn’t much to choose between elafibranor and OCA although Genfit bulls point to safety issues with OCA. The letter from ICPT last year to doctors regarding serious adverse events made their case stronger. But the serious adverse events were due to PBC patients being administered higher than recommended dose of OCA (something we discussed in an article on Seeking Alpha last year). We believe the market overreacted to the issue without looking at the details. In fact, the FDA has not issued a boxed warning or label change for OCA until now and we do not expect that to happen. This in-vitro study also highlights the fact that efficacy wise there is not a lot of difference between the two therapies. As of now, it is hard to say who has the edge in the NASH race. But if we had to stick our neck out, we would give an edge to Intercept. And the reason is Genfit’s decision to go all alone in commercializing elafibranor. At least that is the case as of now. The fact that Intercept already has an established liver franchise gives it a major edge in the NASH market. This is a huge market with a diverse set of prescribing physicians, and marketing outreach and sales can require big funding outlay. ICPT is stronger in that area. This is not to say that we are bearish on Genfit. But we do think Genfit has missed a trick by not finding a commercialization partner for elafibranor. In terms of valuation, both companies look quite attractive right now. Intercept has not recovered since the FDA letter regarding patient deaths with OCA. Genfit on the other hand has failed to take off despite getting some visibility in the U.S. In the end, if we had to make a recommendation, we would go for Genfit for investors with a higher risk appetite. If Genfit succeeds, the upside here could be more. Intercept on the other hand would be a safer bet for investors that are slightly risk averse. Disclosure: I am/we are long GILD. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
The Science Behind Genfit's Elafibranor Elafibranor is an agonist of PPAR alpha and delta. PPARs belong to the nuclear receptor family, which have the potential to be effective in NASH treatment. Elafibranor also has a solid safety profile. In a recent note, we briefly discussed the two leading players in the NASH space: Genfit (OTCPK:GNFTF) and Intercept (ICPT). The note though did not dig deep into the science behind the two drug candidates, Genfit's elafibranor and Intercept's OCA. In this article, we will be focusing on the science behind elafibranor and look to find the reasons the drug candidate is seen as one of the most promising in the NASH space. Elafibranor in NASH Genfit's lead product candidate elafibranor is currently being evaluated in a phase 3 trial, RESOLVE-IT. The pivotal trial is evaluating the efficacy of elafibranor in subjects with NASH Activity Score of = 4. With F2 or F3 fibrosis. The trial's primary endpoint is NASH resolution under the new modified definition (ballooning = 0; inflammation = 0-1) without worsening of fibrosis. RESOLVE-IT is enrolling 2,000 patients (1,000 patients for an interim analysis) and data readout is expected in 2019 (interim analysis). This data, though, if positive, would support elafibranor's marketing application in both the U.S. and Europe. The trial will remain blinded after interim analysis and will continue post-marketing to confirm the long-term benefits of NASH resolution with elafibranor 120 mg dose. Science Behind Elafibranor Elafibranor is a dual peroxisome proliferator-activated receptor (PPAR) agonist. PPAR agonists have been found to be one of the most promising classes of anti-diabetic drugs. They have also shown to improve obesity-induced insulin resistance. There is a strong link between obesity and diabetes and non-alcoholic fatty liver disease (NAFLD), with the disease affecting 70-80% of individuals with obesity and diabetes (Chalasani, N. et al). This is the reason PPAR agonists hold so much promise in the treatment of NASH. PPAR agonists have shown to improve blood glucose levels and levels of blood lipids. PPARs belong to the nuclear receptor family and have three sub-types: PPAR-alpha, PPAR-gamma, and PPAR-delta or beta. Intercept's OCA is also a nuclear receptor. Elafibranor is an agonist of PPAR-alpha and PPAR-delta. PPAR-alpha plays a role in the breakdown and transport of fatty acids in the body. It also plays a role in reducing inflammation and this makes it interesting in the treatment of NASH. PPAR-delta, which is produced in cells throughout the body, plays a role in energy metabolism and reducing inflammation.seekingalpha.com/article/4140520-scie...
The NASH market is still under evaluated by the market. The fourth first drugs reaching the market could become blockbusters only because of the market size. The positive is that those biotech shares have come under a lot of pressure, reducing the risk/reward situation at these lower levels. An investment in only one candidate in NASH is highlyspeculative but if you bet on four or more candidates, you’ll reducedrastically your risk.seekingalpha.com/instablog/35674515-g...
Genfit 35% Low valuation, potential biggest profits Galectin 20% Low valuation, potential lucrative part of small market segment Galmed 10% Low valuation, bet on results Gilead 10% Three drug candidates on NASH Madrigal 10% High valuation, but encouraging potential Intercept 10% Low valuation, potential first drug on market Conatus 5% Low valuation, bet on resultswww.nashbiotechs.com/nash-biotech-ana...
Volgens Boursorama hebben Amerikaanse analisten een nieuw koersdoel van 105 Euro voor Genfit geformuleerd. Dat verklaart wellicht de koersstijging van vandaag met 8%.
HC Wainwright dope Genfit avec un objectif à 105 euroswww.boursier.com/actions/actualites/n...
[quote alias=Brouya id=10704553 date=201803121422] HC Wainwright dope Genfit avec un objectif à 105 euroswww.boursier.com/actions/actualites/n... Er staat ons de komende dagen/weken dus weer een mooie rit opwaarts te wachten.
GlobeNewswireMarch 13, 2018 2017: a year of very significant reinforcement of the cash position (€274M at 12.31.2017), with all programs in the Company`s pipeline moving forward Financial results reflect in particular the signficiant ramp-up of the phase 3 RESOLVE-IT study of elafibranor in NASH and the €180M convertible bond issuance in Fall 2017 Important progress in all of the Company`s other development programs and in particular those that are the most advanced: in vitro diagnostic and pediatric NASH; clinical development of elafibranor in PBC Results of the phase 2 study of elafibranor in PBC and filing of an IND application for the launch of a phase 2 study in fibrosis expected in 2018 Lille (France), Cambridge (Massachusetts, United States), March 13, 2018 - GENFIT (Euronext: GNFT - ISIN: FR0004163111), a biopharmaceutical group at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announces its annual financial results for 2017. A summary of the consolidated financial statements is included in this press release. The 2017 annual consolidated financial statements are available on the "Investors" page of the GENFIT website. Jean-François Mouney, Chairman & CEO of GENFIT, commented: "All programs in the pipeline, particularly those that are the most advanced, have moved forward or have reached significant milestones in 2017; whether it is the phase 3 clinical development program of elafibranor in NASH; phase 2 clinical development program evaluating elafibranor in PBC, which mid-year entered its active recruitment phase; or even our NASH in vitro diagnostic (IVD) program that successfully completed its feasibility phase and began its development phase last June.
Conatus Pharma shares fall on liver-drug study data Published: Apr 4, 2018 5:05 p.m. ET By Wallace Witkowski Reporter Conatus Pharmaceuticals Inc. CNAT, -31.78% shares dropped in the extended session after the biotech company said a clinical study of its liver disease treatment did not reach its goals. Conatus shares, which had been halted before the announcement, fell 27% after hours, following a 2.6% gain to close at $6.01 in the regular session. The company said its drug emricasan did not show a significantly better overall response rate compared with placebo in liver transplant patients with fibrosis or cirrhosis. Back in December 2016, shares had more than doubled after the company announced a licensing and collaboration deal with Novartis for emricasan.
Voor wat het waard is. Genfit - Integrated Strategy For The Management Of NASH Offers Upside Potential Apr. 5, 2018 12:51 PM ET | Kailyn Hui Biotech, healthcare Summary Elafibranor and BMGFT03 (NASH diagnostic biomarkers program) are the key revenue drivers. BMGFT03 IVD test for NASH screening and detection provides NASH market expansion potential and effectively maximizes the sales of Elafibranor. Elafibranor phase 3 intermediary results are expected in 3Q 2019. BMGFT03 is expected to be commercialized in 2020/2021. Editor's note: Seeking Alpha is proud to welcome Kailyn Hui as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more » Genfit (OTCPK:GNFTF) is a biopharmaceutical company specializing in the discovery and development of therapeutic and diagnostic solutions in the area of metabolic, inflammatory, autoimmune and fibrotic diseases, in particular liver and gastrointestinal diseases. The company's pipeline includes Elafibranor (NASH, PBC), NASH diagnostic biomarkers program (BMGFT03), TGFTX4 program (anti-fibrotic) and TGFTX1 program (inflammatory and autoimmune diseases). The company was founded in 1999 with headquarters in Loos, France, and a U.S. subsidiary in Cambridge, Massachusetts. Investment Thesis I believe Elafibranor and BMGFT03 programs are the key drivers of revenue growth. The global NASH market is forecast to reach US$15-20 billion by 2025. Currently, opinions primarily focus on the therapeutic area when evaluating the company, whereas the NASH diagnostic biomarker has been overlooked; the global NASH biomarker market is forecast to reach US$2 billion by 2025 according to Grand View Research. Elafibranor has been granted fast track designation by the FDA. A phase 3 clinical trial for the treatment of NASH, RESOLVE-IT, has started to evaluate the beneficial effect and safety against placebo in NASH patients with F2 or F3 fibrosis. The phase 3 intermediary results are expected in 3Q 2019 and marketing authorization is planned in 2020. Elafibranor is also being evaluated in a phase 2B clinical trial for the pediatric NASH, and a phase 2 clinical trial for primary biliary cholangitis (PBC). NASH is a liver disease causing scarring and inflammation, leading to cirrhosis, liver failure, liver cancer, and increase the risk of cardiovascular problems. The total addressable market of NASH in the US is about 16 million cases in 2015, and it is projected to reach 27 million cases in 2030. The BMGFT03 program aims to develop a non-invasive and easy-to-access diagnostic blood test for the detection and management of NASH, as well as optimize the clinical outcomes by identifying patients who best respond to Elafibranor or any other suitable treatment. The total addressable market of the NASH IVD test is immense. It potentially includes NASH patients and patients at risk - overweight, obese, type 2 diabetes, prediabetes and NAFLD population. For instance, the NAFLD population in the US is about 83 million cases in 2015, and it is projected to reach 100 million cases by 2030. The BMGFT03 program has started the development phase in 2017 and is expected to be launched in 2020/2021. Catalyst Calendar Here I summarize the catalysts in a table below. The catalysts could create significant value through pipeline de-risking and commercialization. Valuation Following is my revenue projection: I assume the price of Elafibranor at €4,600 per course of treatment based on the price of Ocaliva, a treatment for PBC currently being evaluated in Phase 3 clinical trial for NASH, which costs US$5,700 per course. NASH IVD test is at 30% of the market penetration. Based on my projection, Elafibranor revenues will peak at ~€1.6 billion and the NASH IVD test will peak at ~€700 million in 2029E. Price Target US$125 (€101) The price target is derived from my discounted cash flows analysis that uses a WACC of 16.72% and 2% terminal growth. Revenue drivers in my model are Elafibranor for NASH patients with F2-F3 fibrosis and the NASH IVD test would launch in 2020E; the revenue projection is shown above. These assumptions produce the following unlevered free cash flow result and a price target at €101 per share. The model shows 300% upside potential with Genfit currently trading at €23.36. Bull US$205 (€166) In the bull case, I assume BMGFT03 IVD test for NASH screening and detection provides NASH market expansion potential and effectively maximizes the sales of Elafibranor with quick market adoption. Bear US$44 (€36) In the bear case, I assume Elafibranor fails in NASH. However, the diagnostic test performance would not be affected and launch in 2020E. (Source: Genfit) Conclusion I recommend buying Genfit which currently trades at US$29 per share. I believe Elafibranor and the NASH IVD test are the key revenue drivers which offer significantly more upside. I expect the share price to trend higher in a range of US$44-205.
www.genfit.com/wp-content/uploads/201... GENFIT: Major Milestone for the RESOLVE-IT Phase 3 Trial on the Recruitment of the Interim Analysis Cohort - Recruitment of the patient cohort for accelerated approval has been reached - Interim baseline data on the first 1,000 randomized patients shows good distribution of patient recruitment worldwide Lille (France), Cambridge (Massachusetts, United States), April 11, 2018 – GENFIT (Euronext: GNFT - ISIN: FR0004163111), a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announced that the RESOLVE-IT trial in NASH and fibrosis has reached the target recruitment for the interim cohort analysis. GENFIT’s phase 3 registration trial RESOLVE-IT is an international study evaluating the efficacy and safety of elafibranor 120mg once daily in patients with NASH and fibrosis. The primary endpoint is the resolution of NASH without worsening of fibrosis after 72 weeks of treatment. The recruitment of the patients needed for this analysis has been completed. The analysis of this histological endpoint will serve as the basis for accelerated approval under Subpart H in the US and international market approval. The phase 3 will continue to enroll the full cohort for long term clinical benefit analysis, based on progression to cirrhosis, mortality, and liver-related outcomes. The recruitment has also been achieved for the exploratory arm of patients with F1 stage fibrosis. As initially announced, focus has been made on the balanced distribution of treatments across all sites and countries, based on stratification according to gender, diabetes, and disease severity. In the international setting, patients have been enrolled in more than 250 sites across North America, Europe, Australia, Latin America, Turkey and South Africa. Interim baseline data on the first 1,000 randomized patients show that these NASH patients have metabolic co-morbidities, with 48% having type 2 diabetes, 59% having hypertension, and 51% having dyslipidemia. The average BMI is 34. Hispanics represent 25% of the study population. The baseline characteristics of the study population are in line with the expected associated risk factors for NASH and fibrosis.
Voor morgen: Poster presentations Thursday April 12, 2018 - “Expression profiling of 728 miRNAs in a NASH model identifies excellent correlations of hepatic and circulating miR-34a levels with histological lesions in rats and men”, G. Cordonnier et al. (THU-482) - “Elafibranor and nitazoxanide synergize to reduce fibrosis in a NASH model”, R. Walczak et al. (THU-494) 1 The 53rd Annual Meeting of the European Association for the Study of the Liver (EASL)
NASH! THE INTERIM COHORT RECRUITMENT NEEDED FOR CLINICAL TRIAL PHASE 3 IS REACHED FOR THE TWO LEADERS GENFIT ($GNFTF) announced today (Apr 11 2018) that recruitment of the patient cohort (1000 patients) for accelerated approval has been reached in RESOLV’IT. Intercept ($ICPT) announced in may 2017 that they had closed interim recruitment (750 patients) in REGENERATE. GENFIT provided details on this recruitment and that baseline data on the first 1,000 randomized patients shows good distribution of patient recruitment worldwide. As their Phase 2b was jeopardized because of a fast non-balanced recruitment, GENFIT decided to take its time on phase 3. They selected cohort regarding balanced distribution of treatments across all sites and countries, based on stratification according to gender, diabetes, and disease severity. In the international setting, patients have been enrolled in more than 250 sites across North America, Europe, Australia, Latin America, Turkey and South Africa. The purpose of this is clear, they bet on an accelerated FDA approval because of their representative cohort. They learned from the delayed agreement of OCA in PBC because of a non-representative panel of patients that was different from FDA expectations. We can hope that INTERCEPT also learned from that, because as they planned initially to recruit 1400 patients for interim results, they announced in march 2017 that they decided to reduce the cohort to 750 only and never transmitted data’s on their interim cohort profile. This choice seems mainly conducted by their decision to keep the lead on timing but will undoubtedly weak the future strength of REGENERATE trial. The number of patients recruited by arm for interim results will be 250 and one can bet that, at the end, because of potential aborts, results would be presented on less than 230 patients per arm. To compare, ELAFIBRANOR arm in interim results of RESOLV’IT will include 666 patients and, because of potential aborts, results would be presented on almost 600 patients. If the ELAFIBRANOR Cohort is very well balanced as GENFIT declared, the time lost in recruitment selection can be recovered in FDA analysis and accelerated agreement. It would be interesting for INTERCEPT to provide some data’s on their interim recruitment baselines to let analysts evaluate a possible misfit in future agreement delay from the FDA. G Divry
Pl4 schreef op 12 april 2018 15:20 :
www.streetinsider.com/Management+Comm... Genfit open for takeover cited the CEO
Vertaling: ze verwachten slechte resultaten van hun NASH-geneesmiddel.
DeZwarteRidder schreef op 12 april 2018 15:40 :
[...]
Vertaling: ze verwachten slechte resultaten van hun NASH-geneesmiddel.
Zou kunnen. Vooralsnog hebben ze wel een betere recruitering gedaan dan concurrent. We zullen zien.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee